Clinical Trial

The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated October 16, 2024 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
A multi-center, prospective, open-label, randomized controlled study of efficacy and safety of Iguratimod in patients with Primary Sjögren's syndrome
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT04981145
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions Primary Sjögren's Syndrome
Enrollment 78 participants
Start Date 2022-01-14
Primary Completion 2024-12 (estimated)
Study Completion 2025-07 (estimated)
Updated on ClinicalTrials.gov 2024-10-16